Maravai LifeSciences (NASDAQ:MRVI) Lowered to Neutral Rating by Robert W. Baird

Robert W. Baird downgraded shares of Maravai LifeSciences (NASDAQ:MRVI) from an outperform rating to a neutral rating in a report issued on Wednesday, Marketbeat.com reports. Robert W. Baird currently has $3.00 price objective on the stock, down from their prior price objective of $9.00.

Other analysts have also recently issued reports about the company. The Goldman Sachs Group cut Maravai LifeSciences from a “neutral” rating to a “sell” rating and lowered their price target for the company from $7.00 to $4.25 in a research note on Thursday, December 5th. William Blair reaffirmed a “market perform” rating on shares of Maravai LifeSciences in a research note on Friday, November 8th. Wolfe Research started coverage on shares of Maravai LifeSciences in a research report on Thursday, November 14th. They set a “peer perform” rating on the stock. Royal Bank of Canada lowered their price objective on shares of Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a research report on Friday, November 8th. Finally, Guggenheim initiated coverage on Maravai LifeSciences in a report on Thursday, December 19th. They set a “neutral” rating on the stock. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Maravai LifeSciences has an average rating of “Hold” and a consensus price target of $9.46.

Maravai LifeSciences Trading Up 3.5 %

NASDAQ MRVI opened at $3.25 on Wednesday. Maravai LifeSciences has a 12 month low of $2.93 and a 12 month high of $11.56. The stock has a 50-day simple moving average of $4.93 and a 200 day simple moving average of $6.55. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. The company has a market capitalization of $820.72 million, a PE ratio of -1.98 and a beta of -0.08.

Insider Activity at Maravai LifeSciences

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $5.03, for a total transaction of $125,750.00. Following the completion of the transaction, the general counsel now owns 167,618 shares in the company, valued at approximately $843,118.54. This represents a 12.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.63% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Delta Investment Management LLC raised its position in Maravai LifeSciences by 285.4% in the 4th quarter. Delta Investment Management LLC now owns 332,993 shares of the company’s stock valued at $1,815,000 after buying an additional 246,592 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Maravai LifeSciences by 22.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 251,214 shares of the company’s stock worth $1,369,000 after acquiring an additional 45,454 shares in the last quarter. Systematic Financial Management LP raised its holdings in shares of Maravai LifeSciences by 2.3% in the fourth quarter. Systematic Financial Management LP now owns 1,649,544 shares of the company’s stock valued at $8,990,000 after purchasing an additional 37,383 shares during the last quarter. Sherbrooke Park Advisers LLC bought a new stake in shares of Maravai LifeSciences in the fourth quarter worth $78,000. Finally, ProShare Advisors LLC boosted its holdings in Maravai LifeSciences by 89.8% during the fourth quarter. ProShare Advisors LLC now owns 55,488 shares of the company’s stock worth $302,000 after purchasing an additional 26,251 shares during the last quarter. 50.25% of the stock is owned by institutional investors and hedge funds.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.